FDA Eyes Ariad Leukemia Drug After Blood Clot Reports

Law360, New York (October 11, 2013, 4:34 PM EDT) -- Ariad Pharmaceuticals Inc.’s leukemia drug Iclusig has drawn the scrutiny of federal regulators amid growing reports of blood clots among patients taking the medication, the U.S. Food and Drug Administration said Friday after Ariad announced plans to stop admitting new patients into clinical trials for the drug.

Although the Iclusig already comes with a boxed warning — among the most serious warning labels for medications — that it poses risks of blood clots, the most recent clinical trial results showed a higher risk of developing blood...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.